About US
Contact us
-
Analyst chastises Mylan—not known for its transparency—for under-the-radar dealmakingMylan unveiled plenty of news in its second-quarter earnings release last week, including that its revenues were down year over year and that it was lowering guidance. But there was also some key info2018/8/17
-
As biosimilars loom, Roche's Genentech plans to lay off 223 staffers in CaliforniaAs Roche braces for the biosimilar assault on blockbuster cancer drugs, its Genentech unit is parting ways with 223 staffers in California. In a WARN notice posted on the state’s website, Genentechd2018/8/16
-
AIDS health group brings Gilead patent skirmish to Supreme CourtThe AIDS Healthcare Foundation (AHF) has been battling Gilead over its patents on tenofovir alafenamide fumarate (TAF) since January of 2016. When its federal lawsuit alleging the company manipulate2018/8/15
-
After FDA about-face, Amicus' Galafold nabs Fabry disease nod to challenge SanofiOnce thought unlikely to reach the U.S. until 2020 because of an FDA roadblock, Amicus Therapeutics’ Fabry disease drug Galafold won a green light Friday. Now, to duel with Sanofi's standard therapy2018/8/14
-
States say Alvogen lawsuit is part of a 'guerilla' war against the death penaltyIn a battle over lethal execution drugs manufactured by pharma companies, 15 states have backed Nevada in a case alleging drugmaker Alvogen filed a meritless lawsuit only to delay an execution proce2018/8/13
-
China targets Cosentyx, Shingrix and Luxturna and 45 other drugs for priority approvalHey, Big Pharma stars: China wants you. Aiming to speed new drugs to market, China just came up with a target list of 48 treatments greenlighted abroad, including some of the industry's biggest names.2018/8/10
-
Johnson & Johnson CEO Alex Gorsky dines with Trump as president promises ‘substantial’ drug price cutsJohnson & Johnson CEO Alex Gorskyjoined other CEOs fordinner with President Donald Trump and it came with a prelude where Trump told reporters the administration has a planto bringdrug pricesdow2018/8/9
-
Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the processZurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound up on the scrap heap. On Monday, Ironwood Pharmaceuticals said it would end its Zurampic (lesinurad) lic2018/8/7
-
With IPO filing, Lilly pulls back the curtain on animal health business Elanco—warts and allThat was fast. Little more than a week after investors applauded Eli Lilly's plan to spin off its animal health unit, Elanco, the company has delivered. Itfiled a registration statement with the SE2018/8/6
-
Teva's Copaxone holds its own in wake of Mylan's generic price cutMylan may have toppled list prices on its generic Copaxone, but Teva isn’t worried. After far surpassing quarterly expectationsfor the multiple sclerosis blockbuster in the second quarter, the Israe2018/8/3